4CBT

Design, synthesis, and biological evaluation of potent and selective Class IIa HDAC inhibitors as a potential therapy for Huntington's disease


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.03 Å
  • R-Value Free: 0.273 
  • R-Value Work: 0.211 
  • R-Value Observed: 0.215 

wwPDB Validation   3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.

Burli, R.W.Luckhurst, C.A.Aziz, O.Matthews, K.L.Yates, D.Lyons, K.A.Beconi, M.McAllister, G.Breccia, P.Stott, A.J.Penrose, S.D.Wall, M.Lamers, M.Leonard, P.Muller, I.Richardson, C.M.Jarvis, R.Stones, L.Hughes, S.Wishart, G.Haughan, A.F.O'Connell, C.Mead, T.McNeil, H.Vann, J.Mangette, J.Maillard, M.Beaumont, V.Munoz-Sanjuan, I.Dominguez, C.

(2013) J Med Chem 56: 9934-9954

  • DOI: 10.1021/jm4011884
  • Primary Citation of Related Structures:  
    4CBT, 4CBY

  • PubMed Abstract: 
  • Inhibition of class IIa histone deacetylase (HDAC) enzymes have been suggested as a therapeutic strategy for a number of diseases, including Huntington's disease. Catalytic-site small molecule inhibitors of the class IIa HDAC4, -5, -7, and -9 were developed ...

    Inhibition of class IIa histone deacetylase (HDAC) enzymes have been suggested as a therapeutic strategy for a number of diseases, including Huntington's disease. Catalytic-site small molecule inhibitors of the class IIa HDAC4, -5, -7, and -9 were developed. These trisubstituted diarylcyclopropanehydroxamic acids were designed to exploit a lower pocket that is characteristic for the class IIa HDACs, not present in other HDAC classes. Selected inhibitors were cocrystallized with the catalytic domain of human HDAC4. We describe the first HDAC4 catalytic domain crystal structure in a "closed-loop" form, which in our view represents the biologically relevant conformation. We have demonstrated that these molecules can differentiate class IIa HDACs from class I and class IIb subtypes. They exhibited pharmacokinetic properties that should enable the assessment of their therapeutic benefit in both peripheral and CNS disorders. These selective inhibitors provide a means for evaluating potential efficacy in preclinical models in vivo.


    Organizational Affiliation

    BioFocus , Chesterford Research Park, Saffron Walden, Essex, CB10 1XL, United Kingdom.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
HISTONE DEACETYLASE 4A, B, C395Homo sapiensMutation(s): 0 
Gene Names: HDAC4KIAA0288
EC: 3.5.1.98
Find proteins for P56524 (Homo sapiens)
Explore P56524 
Go to UniProtKB:  P56524
NIH Common Fund Data Resources
PHAROS:  P56524
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
9F4IC50:  60   nM  BindingDB
9F4IC50 :  50   nM  PDBBind
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.03 Å
  • R-Value Free: 0.273 
  • R-Value Work: 0.211 
  • R-Value Observed: 0.215 
  • Space Group: P 32
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 104.41α = 90
b = 104.41β = 90
c = 88.44γ = 120
Software Package:
Software NamePurpose
REFMACrefinement
PHASERphasing

Structure Validation

View Full Validation Report



Entry History 

Revision History  (Full details and data files)

  • Version 1.0: 2013-12-11
    Type: Initial release
  • Version 1.1: 2014-01-15
    Changes: Database references
  • Version 1.2: 2018-02-07
    Changes: Database references, Structure summary